Clearmind Medicine Secures U.S. Patent for Binge Behavior Regulators — Clearmind Medicine Inc.

Event summary

Clearmind Medicine Inc. received U.S. Patent No. 12,357,590 titled 'BINGE BEHAVIOR REGULATORS' on June 29, 2026.
The patent strengthens intellectual property protection for the MEAI molecule and related derivatives targeting binge behaviors.
This is the company's second U.S. patent in this area, following Patent No. 12,350,242.
Clearmind now holds nineteen patent families with thirty-two granted patents globally.

The big picture

Clearmind Medicine is fortifying its intellectual property arsenal, a critical move as the biotech sector increasingly relies on patent protection to secure market share. The company's focus on non-hallucinogenic neuroplastogens positions it uniquely in addressing under-treated health problems like alcohol use disorder, where traditional treatments often fall short.

What we're watching

Patent Portfolio Expansion: Whether Clearmind can sustain its aggressive patent filing strategy to maintain competitive advantage in the neuroplastogens space.
Regulatory Approvals: The pace at which regulatory bodies will approve compounds derived from Clearmind's patented molecules for commercial use.
Market Differentiation: How the company's focus on non-hallucinogenic therapeutics will position it against competitors in treating alcohol use disorder and other compulsive disorders.